We evaluated the safety of ILK-treatment at four weeks after adenoviral delivery, especially in view of its propensity to induce angiogenesis and proliferation, but no neoplasia was detected in the liver, kidney or spleen of treated rats. Here, ILK is linked to neoplasm.